This “MAP kinase kinase 1 inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in MAP kinase kinase 1 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
MAP kinase kinase 1 inhibitors Understanding
MAPK kinases 1 and 2 (commonly known as MEK1-2) represent such proteins as they lie downstream of important drug targets for oncology, such as EGFR, RAS and RAF. MEK inhibitors hold promise for use as combination therapies for highly prevalent, genetically defined cancers owing to the critical role that the MAPK pathway plays in the growth and proliferation of many cancer types (including lung cancer, melanoma, pancreatic cancer, colorectal cancer, endometrial cancer, and ovarian cancer).
Report Highlights
This segment of the MAP kinase kinase 1 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
MAP kinase kinase 1 inhibitors Emerging Drugs
Selumetinib: AstraZeneca
Selumetinib is a MEK 1/2 inhibitor used in pediatric patients to treat neurofibromatosis type 1 (NF1) accompanied by symptomatic, inoperable plexiform neurofibromas (PN). Selumetinib is a non-ATP-competitive mitogen-activated protein kinase kinase 1 and 2 (MEK1 and MEK2) inhibitor.6 By selectively targeting MEK1 and MEK2, selumetinib is able to inhibit oncogenic downstream effects of the Raf-MEK-ERK signaling pathway, which is often overactive in certain types of cancer.
Mirdametinib: SpringWorks Therapeutics
Mirdametinib is an oral, allosteric, small molecule MEK inhibitor in development as a monotherapy treatment for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) and low-grade glioma (LGG), and as a combination therapy for the treatment of several subsets of biomarker-defined metastatic solid tumors. A Phase 2 investigator-initiated trial of mirdametinib in adolescents and adults with NF1-PN showed encouraging efficacy along with a generally well-tolerated safety profile. The U.S. Food and Drug Administration (FDA) and the European Commission granted Orphan Drug designation for mirdametinib for the treatment of NF1, and the FDA granted Fast Track designation for the treatment of patients ≥ 2 years of age with NF1-PN that are progressing or causing significant morbidity.
This segment of the report provides insights about the different MAP kinase kinase 1 inhibitors drugs segregated based on following parameters that define the scope of the report.
There are approx. 6+ key companies which are developing the MAP kinase kinase 1 inhibitors. The companies which have their MAP kinase kinase 1 inhibitors drug candidates in the most advanced stage, i.e. Phase II include, SpringWorks Therapeutics .
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
MAP kinase kinase 1 inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses MAP kinase kinase 1 inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging MAP kinase kinase 1 inhibitors drugs.
Geography Covered
- Global coverage
MAP kinase kinase 1 inhibitors Understanding
MAP kinase kinase 1 inhibitors: Overview
MAPK kinases 1 and 2 (commonly known as MEK1-2) represent such proteins as they lie downstream of important drug targets for oncology, such as EGFR, RAS and RAF. MEK inhibitors hold promise for use as combination therapies for highly prevalent, genetically defined cancers owing to the critical role that the MAPK pathway plays in the growth and proliferation of many cancer types (including lung cancer, melanoma, pancreatic cancer, colorectal cancer, endometrial cancer, and ovarian cancer).
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence MAP kinase kinase 1 inhibitors R&D. The therapies under development are focused on novel approaches for MAP kinase kinase 1 inhibitors.
MAP kinase kinase 1 inhibitors Emerging Drugs Chapters
This segment of the MAP kinase kinase 1 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
MAP kinase kinase 1 inhibitors Emerging Drugs
Selumetinib: AstraZeneca
Selumetinib is a MEK 1/2 inhibitor used in pediatric patients to treat neurofibromatosis type 1 (NF1) accompanied by symptomatic, inoperable plexiform neurofibromas (PN). Selumetinib is a non-ATP-competitive mitogen-activated protein kinase kinase 1 and 2 (MEK1 and MEK2) inhibitor.6 By selectively targeting MEK1 and MEK2, selumetinib is able to inhibit oncogenic downstream effects of the Raf-MEK-ERK signaling pathway, which is often overactive in certain types of cancer.
Mirdametinib: SpringWorks Therapeutics
Mirdametinib is an oral, allosteric, small molecule MEK inhibitor in development as a monotherapy treatment for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) and low-grade glioma (LGG), and as a combination therapy for the treatment of several subsets of biomarker-defined metastatic solid tumors. A Phase 2 investigator-initiated trial of mirdametinib in adolescents and adults with NF1-PN showed encouraging efficacy along with a generally well-tolerated safety profile. The U.S. Food and Drug Administration (FDA) and the European Commission granted Orphan Drug designation for mirdametinib for the treatment of NF1, and the FDA granted Fast Track designation for the treatment of patients ≥ 2 years of age with NF1-PN that are progressing or causing significant morbidity.
MAP kinase kinase 1 inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different MAP kinase kinase 1 inhibitors drugs segregated based on following parameters that define the scope of the report.
Major Players working on MAP kinase kinase 1 inhibitors
There are approx. 6+ key companies which are developing the MAP kinase kinase 1 inhibitors. The companies which have their MAP kinase kinase 1 inhibitors drug candidates in the most advanced stage, i.e. Phase II include, SpringWorks Therapeutics .
Phases
This report covers around 6+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
MAP kinase kinase 1 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
MAP kinase kinase 1 inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses MAP kinase kinase 1 inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging MAP kinase kinase 1 inhibitors drugs.
MAP kinase kinase 1 inhibitors Report Insights
- MAP kinase kinase 1 inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
MAP kinase kinase 1 inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Scenario and Emerging Therapies:
- How many companies are developing MAP kinase kinase 1 inhibitors drugs?
- How many MAP kinase kinase 1 inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of MAP kinase kinase 1 inhibitors?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the MAP kinase kinase 1 inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for MAP kinase kinase 1 inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- AstraZeneca
- SpringWorks Therapeutics
- Array BioPharma
- Novartis
- Chongqing Fochon Pharmaceutical
- Recursion Pharmaceuticals
- CStone Pharmaceuticals
Key Products
- Selumetinib
- Mirdametinib
- Binimetinib
- Trametinib
- FCN 159
- REC 4881
- CS 3006
Table of Contents
IntroductionExecutive Summary
MAP kinase kinase 1 inhibitors: Overview
- Structure
- Mechanism of Action
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
MAP kinase kinase 1 inhibitors - Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
Selumetinib: AstraZeneca
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Mirdametinib: SpringWorks Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I and I/II)
- Comparative Analysis
CS 3006: CStone Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Pre-clinical and Discovery Stage Products
- Comparative Analysis
REC 4881: Recursion Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
MAP kinase kinase 1 inhibitors Key Companies
MAP kinase kinase 1 inhibitors Key Products
MAP kinase kinase 1 inhibitors- Unmet Needs
MAP kinase kinase 1 inhibitors- Market Drivers and Barriers
MAP kinase kinase 1 inhibitors- Future Perspectives and Conclusion
MAP kinase kinase 1 inhibitors Analyst Views
MAP kinase kinase 1 inhibitors Key Companies
AppendixList of Tables
Table 1 Total Products for MAP kinase kinase 1 inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for MAP kinase kinase 1 inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- AstraZeneca
- SpringWorks Therapeutics
- Array BioPharma
- Novartis
- Chongqing Fochon Pharmaceutical
- Recursion Pharmaceuticals
- CStone Pharmaceuticals
